NAD+ and Alzheimer's in 2026: What Human Evidence Actually Shows

Short answer: no human outcomes trial has shown that NAD+ infusions, nicotinamide riboside (NR), or nicotinamide mononucleotide (NMN) prevent, slow, or reverse Alzheimer’s or Parkinson’s disease. A 2025 Nature Aging review found a biologically interesting field with unresolved questions about dose, route, long-term safety, individual response, and clinical efficacy.¹

The news cycle made that evidence look newer and more conclusive than it was. A March 2026 institutional story described the review as a possible roadmap for aging and neurodegenerative research, but the paper itself was published on September 9, 2025. It was a review article, not a new patient trial.²

Medical note: NAD+ products are not approved treatments for Alzheimer’s or Parkinson’s disease. A person with cognitive or movement symptoms needs an appropriate clinical assessment. Do not delay established care or change medication for an NAD+ protocol.

Reviewed August 28, 2026. This article now distinguishes the 2025 review from the 2026 news story, removes an invalid trial citation, removes clinic endorsements and dosing advice, and uses the current human evidence boundary.

What the 2025 review actually did

The Nature Aging paper brought together research on NAD+ metabolism, established and newer precursors, clinical translation, production, and measurement. Its abstract says the authors summarized safety, bioavailability, and efficacy data from NAD-related clinical trials, with attention to aging and neurodegenerative disease.¹

Its practical conclusion was cautious. Larger studies are needed to determine:

whether a clinically meaningful benefit exists;
which patients, tissues, or diseases might respond;
the right product, dose, route, and frequency;
long-term safety;
why responses vary between people.

Those are not minor implementation details. They are the questions that must be answered before a plausible mechanism becomes a treatment.

The March 2026 ScienceDaily story was based on material supplied by the University of Oslo and Ullevaal University Hospital. It accurately included the authors’ call for larger and longer trials, but its headline used the promotional phrase “could slow aging and fight Alzheimer’s and Parkinson’s.”² That headline is not a clinical result.

Evidence by claim

Claim	Evidence status in humans	What a buyer should conclude
NAD+ metabolism is involved in cellular energy and signaling	Established biology	Relevance to a pathway does not prove that a supplement treats disease
NAD-related changes are studied in brain aging and neurodegeneration	Active research field	Association and mechanism are not clinical efficacy
Oral NR or NMN can change some NAD-related blood markers	Supported in short human studies	A biomarker response does not show slower cognitive decline
NAD+ precursors improve human aging outcomes consistently	Not established	A 2025 clinical review found limited efficacy and sparse tissue-specific human data³
NAD+ therapy prevents or treats Alzheimer’s or Parkinson’s disease	Not established	Do not use this claim to choose a clinic or replace neurological care
IV delivery is better for the brain than oral precursors	Not established	Route and a higher blood level do not prove brain delivery or patient benefit

This distinction matters because the strongest positive findings often come from cells or animal models. Those studies can identify mechanisms and justify human trials. They cannot tell an individual patient that an infusion or supplement will preserve memory.

The broader human evidence remains limited

A separate 2025 Nature Metabolism review evaluated human evidence for NAD+ decline and precursor supplementation. It found that an age-related decline in human NAD+ had been consistently observed only in a limited number of studies. Human clinical trials of NAD+ precursors had shown limited efficacy, and the published evidence across human tissues remained sparse.³

The wording is important. The field is not disproven, but the commercial claim has moved much faster than the clinical evidence.

For a route-by-route review of IV NAD+, IV NR, oral NR, and NMN, see the WLC NAD+ evidence and safety guide. That review also covers sterile-compounding concerns and the limitations of a small commercial IV pilot.

What was wrong with the earlier version of this article

The previous article crossed several evidence boundaries:

it called the paper a March 2026 Nature Aging publication even though the journal published it in September 2025;
it presented a direct biological chain from age-related NAD+ decline to toxic proteins and neurodegeneration as if human causality were settled;
it cited a purported randomized trial with an invalid DOI;
it described early findings as trends toward cognitive improvement without a valid corresponding source;
it recommended oral doses and IV clinic protocols;
it listed clinics as offering NAD+ without current service verification and assigned a Singapore clinic to the wrong country;
it described exercise as increasing brain NAD+ levels in a way the cited sources did not establish.

Those claims have been removed rather than softened. A citation that shares the topic is not evidence for the sentence attached to it.

Questions to ask when a clinic makes a brain-health claim

A clinic that markets NAD+ for cognition or neuroprotection should answer these questions in writing:

Is the claim about a blood marker, a symptom, a cognitive test, disease progression, or prevention?
Which randomized human trial studied that exact product, route, population, and outcome?
Was the study designed for Alzheimer’s or Parkinson’s disease rather than general wellness?
How long was follow-up, and was the effect clinically meaningful?
Is the proposed product approved for this indication in the relevant jurisdiction?
Who evaluates cognitive symptoms and rules out treatable causes?
How does the clinic coordinate with the patient’s neurologist?
What adverse effects, interactions, and stop rules are documented?
What happens if the treatment changes a laboratory marker but not the patient’s function?

If the supporting answer is a mouse study, a pathway diagram, a company press release, or a rise in blood NAD-related metabolites, the disease-treatment claim remains unsupported.

What patients can do now

People worried about cognitive decline should start with evidence-based evaluation rather than an anti-aging infusion. New or progressive memory problems, impaired daily function, movement changes, sleep problems, medication effects, depression, hearing loss, vascular risk, and other conditions need a proper clinical pathway.

Someone interested in experimental NAD+ research can ask a neurologist about relevant registered trials and eligibility. Trial participation is different from buying an unproven clinic service: it uses a protocol, eligibility criteria, consent, oversight, and predefined outcomes.

Bottom line

NAD+ is a legitimate research topic, not a proven treatment for Alzheimer’s or Parkinson’s disease. The central paper behind the 2026 headlines was a review published in 2025, and its own conclusion was that larger, longer human studies are needed.

Use that uncertainty as a purchasing boundary. Do not pay for a clinic claim that turns mechanism, animal data, or a blood marker into promised neuroprotection.

Zhang J, et al. Emerging strategies, applications and challenges of targeting NAD+ in the clinic. Nature Aging. Published September 9, 2025. ↩ ↩²
University of Oslo and Ullevaal University Hospital. Scientists say NAD+ could slow aging and fight Alzheimer’s and Parkinson’s. ScienceDaily, March 24, 2026. The page identifies the 2025 Nature Aging review as its journal reference. ↩ ↩²
Vinten KT, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nature Metabolism. Published October 13, 2025. ↩ ↩²